ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Published

Journal Article

Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a CD30-positive T-cell non-Hodgkin lymphoma that morphologically resembles ALK-positive ALCL but lacks chromosomal rearrangements of the ALK gene. The genetic and clinical heterogeneity of ALK-negative ALCL has not been delineated. We performed immunohistochemistry and fluorescence in situ hybridization on 73 ALK-negative ALCLs and 32 ALK-positive ALCLs and evaluated the associations among pathology, genetics, and clinical outcome. Chromosomal rearrangements of DUSP22 and TP63 were identified in 30% and 8% of ALK-negative ALCLs, respectively. These rearrangements were mutually exclusive and were absent in ALK-positive ALCLs. Five-year overall survival rates were 85% for ALK-positive ALCLs, 90% for DUSP22-rearranged ALCLs, 17% for TP63-rearranged ALCLs, and 42% for cases lacking all 3 genetic markers (P < .0001). Hazard ratios for death in these 4 groups after adjusting for International Prognostic Index and age were 1.0 (reference group), 0.58, 8.63, and 4.16, respectively (P = 7.10 × 10(-5)). These results were similar when restricted to patients receiving anthracycline-based chemotherapy, as well as to patients not receiving stem cell transplantation. Thus, ALK-negative ALCL is a genetically heterogeneous disease with widely disparate outcomes following standard therapy. DUSP22 and TP63 rearrangements may serve as predictive biomarkers to help guide patient management.

Full Text

Duke Authors

Cited Authors

  • Parrilla Castellar, ER; Jaffe, ES; Said, JW; Swerdlow, SH; Ketterling, RP; Knudson, RA; Sidhu, JS; Hsi, ED; Karikehalli, S; Jiang, L; Vasmatzis, G; Gibson, SE; Ondrejka, S; Nicolae, A; Grogg, KL; Allmer, C; Ristow, KM; Wilson, WH; Macon, WR; Law, ME; Cerhan, JR; Habermann, TM; Ansell, SM; Dogan, A; Maurer, MJ; Feldman, AL

Published Date

  • August 28, 2014

Published In

Volume / Issue

  • 124 / 9

Start / End Page

  • 1473 - 1480

PubMed ID

  • 24894770

Pubmed Central ID

  • 24894770

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2014-04-571091

Language

  • eng

Conference Location

  • United States